Journal
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS
Volume 9, Issue 1, Pages 9-30Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/1756285615612659
Keywords
cannabinoids; CBD; multiple sclerosis; nabiximols; spasticity; THC
Categories
Funding
- Almirall
- Bayer
- Biogen Idec
- Merck Serono
- Novartis
- Sanofi Aventis
- TEVA
- Almirall Hermal GmbH, Reinbek, Germany
Ask authors/readers for more resources
Spasticity, one of the main symptoms of multiple sclerosis (MS), can affect more than 80% of MS patients during the course of their disease and is often not treated adequately. delta-9-Tetrahydrocannabinol-cannabidiol (THC-CBD) oromucosal spray is a plant-derived, standardized cannabinoid-based oromucosal spray medicine for add-on treatment of moderate to severe, resistant multiple sclerosis-induced spasticity. This article reviews the current evidence for the efficacy and safety, with dizziness and fatigue as the most common treatment-related adverse events, being mostly mild to moderate in severity. Results from both randomized controlled phase III studies involving about, 1600 MS patients or 1500 patient-years and recently published studies on everyday clinical practice involving more than 1000 patients or more than, 1000 patient-years are presented.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available